Binimetinib: New Treatment Option for NRAS-Mutant Cutaneous Melanoma Before/After Immunotherapy?

Share this content:
Binimetinib: New Treatment Option for NRAS-Mutant Cutaneous Melanoma Before/After Immunotherapy?
Binimetinib: New Treatment Option for NRAS-Mutant Cutaneous Melanoma Before/After Immunotherapy?

CHICAGO — Binimetinib may represent a new effective therapy for patients with NRAS-mutant melanoma, both before and after immunotherapy. That is the conclusion of the phase 3 NEMO study, results of which were presented at the American Society of Clinical Oncology (ASCO) 2016 Annual Meeting.1

Patients treated with binimetinib, an oral, selective, ATP-uncompetitive inhibitor of MEK1 and MEK2, showed improvements over dacarbazine in several clinically relevant end points, including progression-free survival, overall response rate, and disease control rate and was well-tolerated, said Reinhard Dummer, MD, University Hospital Zurich, Zurich, Switzerland.

The NRAS mutation occurs in approximately 20% of patients with metastatic melanoma; however, no therapies currently exist to treat this specific mutation. Despite emergence of immunotherapies as effective treatments in melanoma, there is a “substantial unmet clinical need, particularly after failure of immunotherapy, he said.

The open-label phase 3 study randomly assigned 402 patients with advanced unresectable/metastatic cutaneous NRAS-mutant melanoma previously untreated or had progressed on/after prior immunotherapy 2:1 to binimetinib 45 mg orally twice daily (n = 269) or dacarbazine 1000 mg/m2 intravenously (n = 133) every 3 weeks.

Progression-free survival was 2.8 months (95% CI, 2.8-3.6) in the binimetinib arm and 1.5 months (95% CI, 1.5-1.7) in the dacarbazine arm (HR, 0.62; 95% CI, 0.47-0.80; P < .001), which was longer in patients with prior immunotherapy (5.5 months) and normal LDH (3.9 months).

Confirmed overall response and disease control rates for binimetinib were 15% (95% CI, 11%-20%) and 58% (95% CI, 52%-64%) for binimetinib vs 7% (95% CI, 3%-13%) and 25% (95% CI, 18%-33%) for dacarbazine (P = .015 [ORR]; P < .001 [DCR]), respectively. Median duration of response on binimetinib was 6.9 months.

Dr. Dummer presented early median overall survival results; which were 11.0 months in the binimetinib arm and 10.1 months in the dacarbazine arm (HR, 1.00; 95% CI, 0.75-1.33; P = .499). Nearly half of patients in both arms used immunotherapy after treatment discontinuation, which included ipilimumab, nivolumab, and pembrolizumab.

Grade 3/4 adverse events reported in 5% or greater of patients in either group were increased CPK (19% binimetinib, 0% dacarbazine), hypertension (7% binimetinib, 2% dacarbazine), anemia (2% binimetinib, 5% dacarbazine) and neutropenia (1% binimetinib, 9% dacarbazine), Dr. Dummer said.



1. Dummer R, Schadendorf D, Ascierto PA, et al. Results of NEMO: A phase III trial of binimetinib (BINI) vs dacarbazine (DTIC) in NRAS-mutant cutaneous melanoma. Oral presentation at: ASCO 2016 Annual Meeting; June 3-7, 2016; Chicago, IL.

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs